CAMK2G and type 2 diabetes mellitus: Furthermore, empagliflozin reduces calmodulin-dependent kinase II (CaMKII) activity and CaMKII-dependent sarcoplasmic reticulum Ca2+ leak, which improves myocardial calcium homeostasis and helps alleviate contractile dysfunction and arrhythmias, offering additional benefits in patients with HF and T2DM [62].